- Nov 9, 2017
- Nov 1, 2017Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual MeetingPresentations Highlight 24-Hour Serial Spirometry Subgroup Findings from Two Replicate Pivotal Phase 3 Studies; Improvements Observed in St. George's Respiratory Questionnaire and COPD Assessment Test Results
- Oct 27, 2017Mylan's EpiPen4Schools® Program Surpasses One Million Free Epinephrine Auto-Injector Donations to U.S. Schools- 2017 marks the five-year anniversary of Mylan's EpiPen4Schools® program.
- Oct 16, 2017
- Oct 5, 2017Mylan, in Partnership with Synthon, Receives Marketing Authorization Approval in Europe for First Generic for Copaxone® 40 mg/mLMylan Has Exclusive Rights for Glatiramer Acetate in Several Key European Markets